MYL - Mylan N.V.

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
39.53
+0.24 (+0.61%)
At close: 4:00PM EST

39.60 +0.07 (0.18%)
After hours: 5:48PM EST

Stock chart is not supported by your current browser
Previous Close39.29
Open39.35
Bid39.25 x 500
Ask39.60 x 100
Day's Range39.11 - 39.99
52 Week Range29.39 - 45.87
Volume6,082,461
Avg. Volume6,318,582
Market Cap21.205B
Beta1.47
PE Ratio (TTM)24.45
EPS (TTM)1.62
Earnings DateFeb 27, 2018 - Mar 5, 2018
Forward Dividend & Yield0.00 (0.00%)
Ex-Dividend Date2007-06-27
1y Target Est43.65
Trade prices are not sourced from all markets
  • UnitedHealth buys DaVita for $4.9B
    Yahoo Finance Video7 days ago

    UnitedHealth buys DaVita for $4.9B

    UnitedHealth is buying Davita Inc’s medical unit for $4.9 billion in cash. Yahoo Finance’s Alexis Christoforous and Rick Newman discuss what it means as the Affordable Care Act mandate is in limbo.

  • TODAY'S CHARTS: Amazon's possible push into pharmacy; Blue Apron soars after replacing CEO
    Yahoo Finance Video12 days ago

    TODAY'S CHARTS: Amazon's possible push into pharmacy; Blue Apron soars after replacing CEO

    The charts of the day include Blue Apron, Mylan and Ulta Beauty.

  • GuruFocus.com7 hours ago

    Analysts Take Action on Health Care Stocks

    Analysts upgraded their ratings on Abbott Labs and Medtronic. The buy rating was confirmed on Mylan, and Citi started covering Aetna

  • Top 10 Generic Pharmaceutical Companies In 2017
    Insider Monkey8 hours ago

    Top 10 Generic Pharmaceutical Companies In 2017

    The top 10 generic pharmaceutical companies in 2017 operate in the relatively recession-proof pharmaceuticals industry which is immune from the vagaries of economic cycles. The huge R&D expense and expertise required to develop new medicines is a big entry barrier and the patent laws allow pharmaceuticals companies to make monopolistic profits for a new product […]

  • Barrons.comyesterday

    Mylan: The Only Specialty Pharma Stock to Buy?

    Guggenheim's Rohit Vanjani and Evan Wang initiated coverage on the speciality pharmaceutical sector today, writing that they're still mostly cautious on the group. Successful manufacturers, Vanjani and Wang write, will have products that are difficult to make, be involved in biosimilars, or diversify their sales away from the U.S. They do have one Buy rated stock in the group, Mylan (MYL), which fits the bill: They write it trades cheaply, does have a promising biosimiliar pipeline, and gets some revenues from outside the U.S. They have a $59 price target on the stock.

  • Stocks making the biggest moves premarket: PEP, MAT, VZ, MYL & more
    CNBCyesterday

    Stocks making the biggest moves premarket: PEP, MAT, VZ, MYL & more

    These are the stocks posting the largest moves before the bell.

  • Teva Dismisses Litigation After Mylan Wins U.S. Court Ruling Related to Teva's Cold Filtration Patents for Copaxone® 40 mg/mL
    PR Newswire2 days ago

    Teva Dismisses Litigation After Mylan Wins U.S. Court Ruling Related to Teva's Cold Filtration Patents for Copaxone® 40 mg/mL

    HERTFORDSHIRE, England and PITTSBURGH, Dec. 11, 2017 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL) today announced that Teva has dismissed its pending district court litigation against Mylan regarding Mylan's Glatiramer Acetate Injection 40 mg/mL, the first generic version of Copaxone® 40 mg/mL. The litigation involved two non-Orange Book listed patents, U.S. Patent Nos.

  • American City Business Journals5 days ago

    Maryland to receive almost $10 million from Mylan over EpiPen charges

    Maryland will receive almost $10 million as part of a settlement agreement with Mylan Inc. related to allegations that the pharmaceuticals company spiked prices of the EpiPen and committed Medicaid fraud. Maryland's coffers will receive $9.98 million as part of a $465 million state-federal settlement between the U.S. Department of Justice and Canonsburg, Pennsylvania-based Mylan and its subsidiary, Mylan Speciality L.P., earlier this year. Company officials said in an August statement that the settlement with the Department of Justice does not contain an admission or finding of wrongdoing.

  • See what the IHS Markit Score report has to say about Mylan NV.
    Markit5 days ago

    See what the IHS Markit Score report has to say about Mylan NV.

    The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.

  • Stocks tread lower, Bitcoin surges to record high
    Yahoo Finance7 days ago

    Stocks tread lower, Bitcoin surges to record high

    Yahoo Finance's LIVE market coverage and analysis of what you need to watch in the stock market begins each day at 9:25 a.m. ET.

  • Pzena Investments Buys Mylan, Hewlett Packard, Wells Fargo
    GuruFocus.com8 days ago

    Pzena Investments Buys Mylan, Hewlett Packard, Wells Fargo

    Fund's largest 3rd-quarter buys

  • Dow soars as Nasdaq struggles, Congress moves on tax bill
    Yahoo Finance9 days ago

    Dow soars as Nasdaq struggles, Congress moves on tax bill

    Yahoo Finance's LIVE market coverage and analysis of stocks and bonds begins each day at 11:45 a.m. ET.

  • Capital Cube9 days ago

    Mylan NV – Value Analysis (NASDAQ:MYL) : December 4, 2017

    Categories: Fundamental Analysis Yahoo FinanceClick here to see latest analysis Capitalcube gives Mylan NV a score of 59. Our analysis is based on comparing Mylan NV with the following peers – Impax Laboratories, Inc., Valeant Pharmaceuticals International Inc, Pfizer Inc., Teva Pharmaceutical Industries Limited Sponsored ADR, Dr. Reddy’s Laboratories Ltd. Sponsored ADR, Lannett Company, Inc. and Sanofi Sponsored ADR ... Read more (Read more...)

  • Mylan Up on FDA Approval & Amazon's Rumored Pharmacy Interest
    Zacks9 days ago

    Mylan Up on FDA Approval & Amazon's Rumored Pharmacy Interest

    Mylan (MYL) receives approval for its biosimilar of breast cancer drug, Herceptin. Amazon is reportedly in talks with Mylan and another generic manufacturer about a potential entry in distribution of drugs.

  • Stocks start in the green despite major tax bill concerns
    Yahoo Finance9 days ago

    Stocks start in the green despite major tax bill concerns

    Yahoo Finance's LIVE market coverage and analysis of what you need to watch in the stock market begins each day at 9:25 a.m. ET.

  • ACCESSWIRE9 days ago

    Today’s Research Reports on Stocks to Watch: Mylan and Nutanix

    NEW YORK, NY / ACCESSWIRE / December 4, 2017 / Shares of Mylan headed higher after revealing an FDA approval for a generic version of Heparin Sodium and after rumors surfaced that the company could be ...

  • GlobeNewswire9 days ago

    Market Trends Toward New Normal in Patterson-UTI Energy, SAExploration, vTv Therapeutics, Outfront Media, Mylan N.V, and Axcelis Technologies — Emerging Consolidated Expectations, Analyst Ratings

    NEW YORK, Dec. 04, 2017-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Patterson-UTI ...

  • MarketWatch9 days ago

    When it comes to high drug prices, Big Pharma blames someone else

    Patients can pay more than a health plan does for their medicine. Drugmakers say that’s the fault of players like health insurers.

  • Mylan and Aspen Announce Launch of Generic Busulfex® Injection
    PR Newswire9 days ago

    Mylan and Aspen Announce Launch of Generic Busulfex® Injection

    HERTFORDSHIRE, England, PITTSBURGH and DURBAN, South Africa, Dec. 4, 2017 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL) and its partner, Aspen (JSE:APN), today announced the U.S. launch of Myleran (busulfan) Injection, 60 mg/10 mL (6 mg/mL) Single-dose Vial, a generic version of Otsuka Pharmaceutical's Busulfex® Injection. Aspen received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product, which is indicated for use in combination with cyclophosphamide as a conditioning regimen prior to allogeneic hematopoietic progenitor cell transplantation for chronic myelogenous leukemia. As part of its partnership with Aspen, Mylan will commercialize Busulfan Injection, 60 mg/10 mL (6 mg/mL) Single-dose Vial in the U.S. Mylan has one of the largest injectable portfolios in the industry and is also one of the largest suppliers of cancer medicines by volume in the U.S.

  • MarketWatch10 days ago

    Mylan and Teva stocks rise on report about Amazon’s pharmacy aims

    Shares of generic drug manufacturers are rising on a report stating that Amazon.com held talks with Mylan and Novartis’ Sandoz about entering the pharmacy business, while shares of distributors and drugstores ...

  • 3 Drug/Biotech Stocks in Focus on World AIDS Day
    Zacks12 days ago

    3 Drug/Biotech Stocks in Focus on World AIDS Day

    On World AIDS Day, we look into some of the key pharma companies in the HIV market that are developing drugs to address the life threatening disease.

  • Mylan Pops After FDA Approves Its Generic Blood Thinner
    Investor's Business Daily12 days ago

    Mylan Pops After FDA Approves Its Generic Blood Thinner

    Mylan popped after it gained approval for a generic blood thinner and amid rumors it's talking to Amazon.

  • Why Ambarella, Foundation Medicine, and Mylan Jumped Today
    Motley Fool12 days ago

    Why Ambarella, Foundation Medicine, and Mylan Jumped Today

    These stocks bucked the market's downward trend. Find out how.

  • American City Business Journals12 days ago

    Mylan shares soar on Amazon reports, FDA approvals

    The U.S. Food and Drug Administration approved both Mylan NV’s generic blood thinner and  breast and stomach cancer treatment . But that may not be the only reason that Mylan’s (Nasdaq:MYL) stock was up ...

  • TODAY'S CHARTS: Amazon's possible push into pharmacy; Blue Apron soars after replacing CEO
    Yahoo Finance12 days ago

    TODAY'S CHARTS: Amazon's possible push into pharmacy; Blue Apron soars after replacing CEO

    Markets (^DJI, ^GSPC, ^IXIC) fell sharply on Friday after ABC reported former national security adviser Michael Flynn will testify that he was directed by Trump to talk to Russians.